Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study.
Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependent drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.
Menczer
J
J
Department of Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Ben-Baruch
G
G
Rizel
S
S
Brenner
H
H
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D012008:Recurrence; D016896:Treatment Outcome
D005047:Etoposide; D002945:Cisplatin